Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct;40(5):1040-1052.
doi: 10.1002/ncp.11348. Epub 2025 Jul 9.

The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review

Affiliations
Review

The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review

Bailey Dunn et al. Nutr Clin Pract. 2025 Oct.

Abstract

Somatostatin is a naturally occurring polypeptide hormone that exerts its effect on the gastrointestinal tract by reducing exocrine and endocrine secretion, resulting in decreased motility, gastric emptying, splanchnic blood flow, fat absorption, lymphatic flow, and gallbladder contraction. Octreotide is a synthetic somatostatin analogue that has a variety of clinical applications in the gastrointestinal tract, including in the treatment of gastrointestinal bleeding, motility disorders, lymphatic disorders, pancreatic disorders, and high-output states. Clinicians may hesitate to use octreotide because of its potential side effects and the lack of robust pediatric data. Here we describe potential side effects of the drug and review the use of octreotide in the above pediatric indications.

Keywords: gastrointestinal bleeding; lymphatic disorders; octreotide; pancreatitis; secretory diarrhea; somatostatin.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Heikenen JB, Pohl JF, Werlin SL, Bucuvalas JC. Octreotide in pediatric patients. J Pediatr Gastroenterol Nutr. 2002;35(5):600‐609. 10.1097/00005176-200211000-00003 - DOI - PubMed
    1. Mosdell KW, Visconti JA. Emerging indications for octreotide therapy, part 1. Am J Hosp Pharm. 1994;51(9):1184‐1192. - PubMed
    1. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246‐254. 10.1056/NEJM199601253340408 - DOI - PubMed
    1. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther. 2001;8(6):409‐415. 10.1097/00045391-200111000-00005 - DOI - PubMed
    1. Testoni D, Hornik CP, Neely ML, et al. Safety of octreotide in hospitalized infants. Early Hum Dev. 2015;91(7):387‐392. 10.1016/j.earlhumdev.2015.04.008 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources